Gene Analysis may Lead to New Treatments for Mental Illnesses

Article

An analysis of the DISC1 gene, which plays a role in mental illness, may lead to improved methods for prescribing targeted medications.

An analysis of the DISC1 gene, which plays a role in mental illness, may lead to improved methods for prescribing targeted medications, according to findings from researchers at the University of Edinburgh, UK, who utilized existing data from the Human Genome Project to examine how the DISC1 gene impacts a number of other genes that current medications are designed to act upon. Their findings, published in the journal PLoS ONE, show that “six DISC1 cis-variants” significantly changed the “expression levels of the DISC1 gene in a semi-dominant fashion (15% average reduction in heterozygotes versus 19% in homozygotes).”

The researchers stated that the ability of the DISC1 variants to change the expression levels of the gene could be important clinically and “be tested by association studies of target genes and expression studies of post-mortem brain tissue.”

The antipsychotic drugs that currently exist for treating illnesses like bipolar disorder and schizophrenia were developed without any direct knowledge of the link between DISC1 and these disorders, according to the researchers. They added that the DISC1 pathway could now provide a more direct target for future drug development and that “DISC1 pathway variant profiling may serve as a useful predictor of individual response to a given therapeutic.”

“We know that disorders such as schizophrenia have a genetic element and that this specific gene, DISC1, is important to that process,” said project leader Dr. William Hennah, Finland Institute for Molecular Medicine. “This research helps us to understand exactly how it affects brain development and provides clues about how to solve problems when that process goes wrong.”

Related Videos
Rebecca A. Andrews, MD: Issues and Steps to Improve MDD Performance Measures
A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data
Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety
Leesha Ellis-Cox: Steps to Closing the Bipolar Disorder Diagnosis Gap for Blacks
Daniel Greer, PharmD: Reduction in Rehospitalizations with Antipsychotic Injections for Schizophrenia
Understanding the Link Between Substance Use and Psychiatric Symptoms, with Randi Schuster, PhD
Andrew Miller, PhD: Inventor of KarXT Discusses Pivotal EMERGENT-2 Data
© 2024 MJH Life Sciences

All rights reserved.